Insider Selling: Axon Enterprise (NASDAQ:AXON) CAO Sells $860,175.00 in Stock

Axon Enterprise, Inc (NASDAQ:AXON) CAO Jennifer Mak sold 1,500 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $573.45, for a total value of $860,175.00. Following the sale, the chief accounting officer owned 12,240 shares of the company’s stock, valued at $7,019,028. This represents a 10.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Axon Enterprise Trading Up 0.6%

Shares of AXON opened at $574.01 on Friday. Axon Enterprise, Inc has a one year low of $396.41 and a one year high of $885.91. The stock has a 50-day moving average price of $536.08 and a 200 day moving average price of $618.84. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53. The company has a market capitalization of $46.15 billion, a P/E ratio of 377.64, a P/E/G ratio of 12.18 and a beta of 1.46.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.55. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The company had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. During the same period in the prior year, the company posted $2.08 EPS. Axon Enterprise’s quarterly revenue was up 38.5% on a year-over-year basis. Sell-side analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on AXON. UBS Group cut their target price on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Morgan Stanley lowered their price objective on Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. Citigroup restated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. Piper Sandler reduced their target price on Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Finally, Needham & Company LLC decreased their target price on Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Sixteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $762.93.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 revenue and bookings beat expectations — Axon reported quarterly revenue of ~$796.7M (up ~38.5% YoY) and said bookings were at record levels, driven by recurring software/services and AI products; investors are rewarding the growth narrative. Read More.
• Positive Sentiment: AI and acquisitions broaden the TAM — Axon is rolling out AI tools (Draft One) and expanding into emergency communications via buys like Carbyne and Prepared, pushing the company from hardware into a higher‑margin, recurring‑revenue public‑safety platform. Read More.
• Positive Sentiment: Hardware momentum in Connected Devices — demand for TASER 10, Axon Body 4 and counter‑drone solutions boosted device sales, helping current revenue strength and cross‑sell into Axon Cloud subscriptions. Read More.
• Neutral Sentiment: Street attention and bull narratives — multiple outlets and bullish newsletters have flagged Axon as a pick, increasing retail/institutional focus but also raising expectations. Read More.
• Negative Sentiment: Profitability collapsed despite revenue growth — quarterly net income plunged (reported near break‑even), compressing EPS and margins; that raises near‑term profitability and margin recovery questions. Read More.
• Negative Sentiment: Insider selling — Axon’s CAO sold 1,500 shares (~$860k), which may be viewed negatively by some investors even though the remaining insider stake remains material. Read More.
• Negative Sentiment: Analysts trimmed targets — some firms cut price targets (Morgan Stanley, Barclays) even as many maintain buy/overweight positions, signaling debate about valuation vs. execution. Read More.
• Negative Sentiment: High valuation and execution risk — AXON trades at a very high P/E, leaving the stock sensitive to execution on margin recovery, successful AI monetization and integration of acquisitions. Read More.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Axon Enterprise by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock worth $5,319,928,000 after acquiring an additional 53,060 shares during the period. Geode Capital Management LLC raised its position in shares of Axon Enterprise by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock worth $1,265,657,000 after purchasing an additional 35,544 shares during the period. Baillie Gifford & Co. lifted its holdings in shares of Axon Enterprise by 1,198.7% in the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock worth $932,869,000 after purchasing an additional 1,516,099 shares during the last quarter. Sands Capital Management LLC lifted its holdings in shares of Axon Enterprise by 11.6% in the 4th quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock worth $914,047,000 after purchasing an additional 167,095 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in Axon Enterprise by 326.9% during the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock valued at $874,463,000 after purchasing an additional 1,179,038 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.